Abstract. Butein is a flavonoid isolated from the bark of Rhus verniciflua Stokes and the flowers of Butea monosperma, and is known to be a potential therapeutic drug for treating inflammation and cancer. Cyclooxygenase (COX) converts arachidonic acid to prostanoids, and increased expression of its isoform, COX-2, has been observed in lung cancer tissue. The aim of the present study was to investigate expression alteration of COX-2 in A549 lung cancer cells following butein treatment at the mRNA and protein levels by quantitative polymerase chain reaction and western blotting, respectively. It was observed that COX-2 mRNA and protein levels were significantly downregulated in the butein treatment group in comparison with the control group (P<0.05). In addition, the effects of butein on proliferation and apoptosis were evaluated. The data demonstrated that butein induces cell-cycle arrest and apoptosis in human lung cancer cells. These results indicated that butein may be a promising candidate drug for lung cancer treatment.
Introduction
The flavonoid butein may be isolated from the bark of Rhus verniciflua Stokes and the flowers of Butea monosperma. It is a biologically active flavonoid, and a number of studies have reported its anticarcinogenic activities (1) (2) (3) . The organic extract purified from Rhus verniciflua Stokes inhibits the growth of transformed hepatic cells, but not the untransformed parent cells (4) , whereas butein alone may introduce G(2)/M phase arrest in hepatic cells (5) . Its anti-proliferative or pro-apoptotic effects may be induced through downregulating STAT3-related gene expression (6) and inhibiting telomerase activity (7) . The flavonoid may also re-sensitize the tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) resistant leukemia cells undergoing apoptosis following TRAIL treatment (8) , and may reduce clonogenic growth of human breast cancer cells (9) . These experiments indicated the potential anticarcinogenic effect of butein on different cell types.
Prostaglandins may be produced from arachidonic acid with the enzyme cyclooxygenase (COX) in tumor tissues. Increased expression of COX-2 in the neovasculature of breast tumors has been observed, which suggests that the enzyme may be involved in the later stage of cancer development. In the estrogen receptor-positive MCF-7 cells, COX-2 overexpression increases the growth rate and colony formation in soft agar, and promotes movement across the Matrigel basement membrane (10) . By contrast, overexpressing COX-2 in the Hs578T estrogen receptor-negative breast cancer cell line also activates matrix metalloproteinase-2 (11). These activities may encourage the invasiveness of cancer cells and facilitate metastasis. Altered gene expression in cell cycle and apoptosis, or their regulatory signals may also support tumorigenesis. Notably, COX-2 may increase the expression of the epidermal growth factor receptor, aromatase, and Bcl-2, which may be integrated into these processes (12) . COX-2 inhibitors have shown a degree of protection against breast carcinogenesis in animal models. Celecoxib inhibits the onset and progression of 7,12-dimethylbenz [a] anthracene-induced mammary tumorigenesis in rats, while nimesulide reduces tumor incidence induced by 2-amino-1-me thyl-6-phenylimidazo [4,5-b] pyridine (13) . These experimental results have demonstrated that COX-2 inhibition may protect against cancer. Therefore, the inhibition of COX-2 has been suggested to be a promising therapeutic strategy for human cancer, thus, indicating the importance of overcoming the therapeutic resistance of cancer and the possible role of COX-2 in cancer. In the current study, the effect of butein on COX-2 expression in human lung cells was investigated. Furthermore, the effects of butein on proliferation and apoptosis in A549 lung cancer cells were evaluated. Cell culture. The A549 non-small cell lung carcinoma (NSCLC) cell line was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM supplemented with heat-inactivated FBS (10%), L-glutamine (2 mM), penicillin (100 IU/ml), and streptomycin (100 µg/ml) in a humidified incubator aerated with 5% CO 2 and 95% at 37˚C. When cells reached 70-80% confluency, they were trypsinized, counted and treated with celastrol in complete cell medium. Control cells were treated with vehicle (DMSO) for the same duration.
Materials and methods

Chemicals
Cell viability assay. Cells were plated in 96-well culture plates at an initial density of 1x10 4 cells/well and allowed to adhere to the plates. The culture medium was replaced by fresh medium containing butein at concentrations ranging between 0 and 20 µmol/l and incubated for 48 h. The cell proliferation kit I (MTT) from Roche Applied Science (Mannheim, Germany) was used to measure cell viability. Briefly, 10 µl labeling solution was added to each well of the 96-well plates. After 2 h in the CO 2 incubator, 100 µl solubilization solution was added to dissolve the purple crystals, which were the products of the MTT substrates. The absorbance was measured at 570 nm by a plate reader (Perkin-Elmer, Waltham, MA, USA). Absorbance measured in the MTT assays is expressed as a percentage of the control (defined as 100%).
Cell cycle analysis. Cells were seeded in 25 cm 2 flasks and incubated overnight to allow cells to adhere to the plate. A549 cells were treated with 10 and 20 µmol/l butein for 24 h. Following treatment, control (untreated) and treated floating and adherent cells were collected by trypsinization. The cells (1x10 6 cells/ml) were washed twice with cold phosphate-buffered saline (PBS) and fixed in 70% ethanol. Immediately prior to the analysis, the cells were washed with PBS and stained with a solution containing propidium iodide (PI; 0.2 mg/ml) for 1 h at 4˚C and with RNase A (0.1 mg/ml) for 30 min at 37˚C. The distribution of cells in the cell cycle was measured by flow cytometry (Becton-Dickinson, Franklin Lakes, NJ, USA). Percentages of cells in the cell cycle phases were calculated using the Cell Quest software (Becton-Dickinson).
Measurement of apoptosis by ELISA. The induction of apoptosis by butein was assayed by the Nucleosome ELISA kit (Fitzgerald Industries International, Acton, MA, USA). This kit uses a photometric enzyme immunoassay to quantitatively determine the formation of cytoplasmic histone-associated DNA fragments (mono and oligonucleosomes) following apoptotic cell death. Apoptosis was determined by ELISA and the A549 cells (1x10 5 ) were treated with butein at 0, 10 and 20 µmol/l for 12, 24 and 48 h in a 96-well plate. The induction of apoptosis was evaluated by assessing the enrichment of nucleosome in the cytoplasm, and determined as described in the manufacturer's instructions for the nucleosome ELISA kit.
Quantitative polymerase chain reaction (qPCR) assay. Cells were seeded in 6-well plates for one day prior to treatment. The medium was removed and cells were cultured in fresh DMEM containing 20 µmol/l butein. Following 6 h treatment, total RNA was extracted from the cells using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). The concentration and purity of RNA were determined by absorbance at 260/280 nm. DNA strands were synthesized from 3 µg total RNA by oligo-dT primers and M-MLV Reverse Transcriptase (Takara Bio, Inc., Shiga, Japan). Target fragments were quantified by real-time PCR, and an ABI prism 7700 Sequence Detection system (Applied Biosystems, Foster City, CA, USA) was employed for this assay. Taqman ® /VIC ® MGB probes and primers for COX-2 [Assay ID (NM_000963.1): HS00153133_M1] and β-actin, and Real-time PCR Taqman Universal PCR Master mix were obtained from Applied Biosystems. PCR reactions were set up as described in the instructions, which was validated by the company. The signal obtained for β-actin was used as a reference housekeeping gene to normalize the quantity of total RNA amplified in each reaction. Relative gene expression data were analyzed using the 2 -ΔΔCt method.
Western blot analysis. Cells were washed once with PBS (pH 7.4) and harvested into a 1.5 ml microtube with 0.5 ml lysis buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). The lysis buffer contained protease inhibitors (40 mg/l PMSF, 0.5 mg/l aprotinin, 0.5 mg/l leupeptin, 1.1 mmol/l EDTA and 0.7 mg/l pepstatin). The harvested cells were then lysed with a cell disruptor (Branson Ultrasonics Corp., Danbury, CT, USA) on ice for 30 sec. The protein concentration of the cell lysate was determined by a Dc protein assay (Bio-Rad, Richmond, 
Results
Butein inhibits the growth of human lung cancer cells.
To evaluate the antiproliferative activities of butein on A549 cells, the MTT assay was applied. As shown in Fig. 1 , exposure of A549 cells to increasing concentrations of butein (0-20 µmol/l) for 72 h resulted in a dose-dependent growth inhibition. The lower butein concentrations (2.5-5 µmol/l) did not affect A549 cell viability significantly, whereas concentrations between 10 and 20 µmol/l significantly reduced cell viability. The IC 50 for the 48 h incubation time was ~14.18 µM. Therefore, 15-20 µmol/l doses were selected for further butein treatment studies.
Butein-induced cell cycle arrest and apoptosis in A549 cells.
The results on the effect of butein on cell cycle progression of A549 are shown in Fig. 2A . As compared with the control, 10 µmol/l butein increased the population of G1 phase from 35.3 to 42.4%. This effect was enhanced when A549 cells were treated with 20 µmol/l butein (61.5% cell population in G1 phase). Fig. 2B shows the time course of DNA fragmentation in continuous treatment with 10 and 20 µmol/l butein. DNA mRNA expression of COX-2 following butein treatment. qPCR was performed to detect the mRNA expression of COX-2 in A549 cancer cells following butein treatment. As shown in Fig. 3 , mRNA levels of COX-2 was significantly reduced following butein treatment as compared with the control group (P<0.05), which showed that mRNA expression of COX-2 was downregulated by butein treatment in A549 cancer cells.
Protein expression of COX-2 in A549 cells following butein treatment. A549 cells were treated with 20 µmol/l butein, and cultured for 24 h. Protein lysates were prepared for western blot analysis. As shown in Fig. 4 , protein levels of COX-2 were significantly reduced in A549 cells following butein treatment compared with the control (P<0.05), which was in agreement with the result that butein treatment may downregulate COX-2 mRNA expression in A549 cancer cells.
Discussion
Lung cancer is the leading cause of cancer-related mortality worldwide. NSCLC accounts for ~75-85% of lung cancer. NSCLCs commonly develop resistance to radiation and chemotherapy, and often present at stages beyond surgical respectability. Since current treatment modalities are inadequate, novel therapies are required to reduce the effects of the increasing incidence in pulmonary neoplasm (14, 15) . Butein is a polyphenolic compound, which may be extracted from the stem bark of cashews and Rhus verniciflua Stokes, and used as a food additive and a traditional herbal medicine. Previous studies suggested that butein exhibits anticancer activity and that butein may induce apoptosis in human promyelocytic leukemia (16) and B16 melanoma cells (17) . In vitro, butein may suppress the proliferation of the majority of human cancers, including breast and colon carcinomas, osteosarcoma, prostate tumor and hepatic stellate cells (3, 9, (18) (19) (20) (21) . The present study indicated that butein inhibits cell proliferation of lung cancer in a dose-dependent manner, which is in agreement with previous studies (3, (18) (19) (20) (21) .
COX-2 is inducible by inflammatory stimuli, including cytokines, growth factors, and tumor promoters, and is upregulated in a variety of malignancies and favors the growth of malignant cells by stimulating proliferation and angiogenesis (22, 23) . In previous years, a large number of studies demonstrated that COX-2 is overexpressed in ovarian cancer (24) (25) (26) . Furthermore, Arico et al (27) found that COX-2 is capable of inducing angiogenesis via the vascular endothelial growth factor and prostaglandin production and may also inhibit apoptosis by inducing the antiapoptotic factor Bcl-2, as well as activating antiapoptotic signaling through Akt/protein kinase B. These results suggest that COX-2 is important in the generation and progression of solid tumors, and that inhibition of COX-2 may inhibit the growth of a variety of solid malignancies. In the present study, butein mediated the downregulation of COX2 expression in human lung cancer cells and induced cancer cell apoptosis, which may be a key molecular mechanism of butein in anticancer therapy.
In conclusion, butein was observed to decrease COX-2 expression in cancerous lung cells in the current study. Considering the importance of COX-2 in lung carcinogenesis, the findings may provide the scientific basis for potential pharmaceutical application of butein.
